Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis-Reference-Cited by-同舟云学术

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

Published:2023-09 Issue: Volume:191 Page:112966
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Corbaux Pauline^ORCID,You Benoit^ORCID,Glasspool Rosalind M.,Yanaihara Nozomu^ORCID,Tinker Anna V.,Lindemann Kristina,Ray-Coquard Isabelle L.,Mirza Mansoor R.,Subtil Fabien,Colomban Olivier^ORCID,Péron Julien,Karamouza Eleni,McNeish Iain^ORCID,Kelly Caroline^ORCID,Kagimura Tatsuo,Welch Stephen,Lewsley Liz-Anne^ORCID,Paoletti Xavier,Cook Adrian^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas;You;Cancer Treat Rev,2021

2. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Int J Gynecol Cancer Off J Int Gynecol Cancer Soc,2019

3. PARP inhibitors in the management of ovarian cancer: ASCO guideline;Tew;J Clin Oncol Off J Am Soc Clin Oncol,2020

4. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG);Rustin;Int J Gynecol Cancer Off J Int Gynecol Cancer Soc,2011

5. The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review;Lauby;Cancers (Basel),2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological PCI as a prognostic marker of survival after neoadjuvant chemotherapy in patients undergoing interval cytoreduction with or without HIPEC in FIGO stage IIIC high grade serous ovarian cancer;Frontiers in Oncology;2024-08-20

2. Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors;Cancers;2024-06-26

3. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer;Biomarkers in Medicine;2024-06-17

4. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study;International Journal of Molecular Sciences;2024-05-11

5. The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer;Cancers;2024-03-24